Dosage form: suspension for subcutaneous injections in 3 ml cartriges and pre-filled disposable insulin pen

Has fast and predictable effect and the elimination typical for physiologic insulin secretion
Prandial component ensures faster and more predictable onest of action as well as fast elimination peculiar to physiologic insulin secretion? extended component ensures smooth peakless profile of basal insulin
Onset of action after subcutaneous administrationin -15 min
Maximum action - in 0.5–2.5 hours
Duration of action up to 15 hours

Pharmacokinetic properties

The pharmacokinetics of insulin lispro reflect a compound that is rapidly absorbed, and achieves peak blood levels 30 to 70 minutes following subcutaneous injection. The pharmacokinetics of insulin lispro protamine suspension are consistent with those of an intermediate acting insulin such as NPH. The pharmacokinetics of RinLis Mix 25 are representative of the individual pharmacokinetic properties of the two components. When considering the clinical relevance of these kinetics, it is more appropriate to examine the glucose utilization curves (as discussed in 5.1).

Renal impairment

Insulin lispro maintains more rapid absorption when compared to soluble human insulin in patients with renal impairment. In patients with type 2 diabetes over a wide range of renal function the pharmacokinetic differences between insulin lispro and soluble human insulin were generally maintained and shown to be independent of renal function.